Digitizing Medicine There are now about 230,000 on
Post# of 22755
There are now about 230,000 ongoing clinical trials for drugs in the U.S., up from about 30,000 a decade ago, Umansky tells Barron's. Meanwhile, using DNA sequencing to select candidates for these clinical trials increases their probabilities of success "exponentially," Umansky adds. About 60% of the gene-sequencing equipment used worldwide is manufactured by Illumina, and this equipment is used in roughly 90% of the gene-sequencing tests performed across the globe, he says. Illumina's market value is now over ten times what it was five and half years ago, and the fund manager expects another ten-fold increase during the next five to ten years.
Digitization is shortening the innovation cycle in biotechnology, Umansky observes. Regeron is his top pick in this area, and he notes that the stock has roughly doubled in price since he purchased it in 2014.
Regeron ==> $REGN,,,$504.90
Illumina ==> $ILMN,,, $172.33
https://twitter.com/twitter/statuses/957208055766241280